An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imlifidase (Primary)
Indications Guillain-Barre syndrome
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms 15HMedIdeS09
Sponsors Hansa Biopharma AB

Most Recent Events

17 Dec 2024 Full Results presented in the Hansa Biopharma AB media release.
17 Oct 2024 According to a Hansa Biopharma AB media release, data read-out expected by year end 2024.
08 Jun 2024 This study has been Completed in Netherlands, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight